Chapman, SR ORCID: https://orcid.org/0000-0002-0326-7742, Fitzpatrick, R and Aladul, M (2017) Patients’ understanding and attitudes towards infliximab and etanercept biosimilars: result of a UK web-based survey. BioDrugs, 31. pp. 439-446.

[img] Text
patients' web survey.docx - Accepted Version

Download (295kB)

Abstract

Background
Infliximab and etanercept biosimilars present significant potential cost savings to the NHS. Patients need to be involved in the decision to use these medicines but there is limited published literature on their knowledge and attitudes about these biosimilars.

Objectives
The aim of this study was to investigate ankylosing spondylitis and rheumatoid arthritis patients’ knowledge and attitudes towards infliximab and etanercept biosimilars in the UK.

Methods
A self-administered web survey was conducted among the members of the National Rheumatoid Arthritis Society and the National Ankylosing Spondylitis Society in the UK between 2 March 2017 and 2 June 2017.

Results
A total of 182 patients participated in this survey. The majority of participants (73%) were on etanercept, and 66 and 80% of patients on originator biologic and biosimilars, respectively, understood what biosimilars were. Patients who were currently on biosimilars had greater confidence in their effectiveness and the doctor’s decision to initiate than those who were originally on originator biologics that doctors proposed to switch to biosimilars. The majority (82%) of participants on biosimilars thought that biosimilars help to save money for the NHS, while just over half (54%) of participants on the originator biologics thought the cost of treatment should not be considered when prescribing biosimilars.

Conclusions
Survey participants had a good knowledge and understanding of biosimilars. Participants on biosimilars were confident and positive about biosimilars’ safety, efficacy and switching, whereas participants on the originator biologics were more reluctant to switch to biosimilars. Those patients who expressed concerns felt that more clinical trials on switching biosimilars, better communication and reassurance by healthcare professional teams and further involvement in decision making would increase their acceptance of biosimilars.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Springer at https://doi.org/10.1007/s40259-017-0238-1 - please refer to any applicable terms of use of the publisher.
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy
Depositing User: Symplectic
Date Deposited: 12 Mar 2021 15:19
Last Modified: 12 Mar 2021 15:23
URI: https://eprints.keele.ac.uk/id/eprint/9246

Actions (login required)

View Item View Item